AR128383A1 - Inhibidores de ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp1) y usos de los mismos - Google Patents

Inhibidores de ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp1) y usos de los mismos

Info

Publication number
AR128383A1
AR128383A1 ARP230100212A ARP230100212A AR128383A1 AR 128383 A1 AR128383 A1 AR 128383A1 AR P230100212 A ARP230100212 A AR P230100212A AR P230100212 A ARP230100212 A AR P230100212A AR 128383 A1 AR128383 A1 AR 128383A1
Authority
AR
Argentina
Prior art keywords
c6alkyl
heterocycloalkyl
cycloalkyl
nrcrd
heteroaryl
Prior art date
Application number
ARP230100212A
Other languages
English (en)
Spanish (es)
Inventor
Xin Cheng
Yingtao Liu
Luoheng Qin
Feng Ren
Huaxing Yu
Original Assignee
Insilico Medicine Ip Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Insilico Medicine Ip Ltd filed Critical Insilico Medicine Ip Ltd
Publication of AR128383A1 publication Critical patent/AR128383A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ARP230100212A 2022-01-28 2023-01-30 Inhibidores de ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp1) y usos de los mismos AR128383A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2022074739 2022-01-28
CN2022140318 2022-12-20

Publications (1)

Publication Number Publication Date
AR128383A1 true AR128383A1 (es) 2024-04-24

Family

ID=87470622

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP230100212A AR128383A1 (es) 2022-01-28 2023-01-30 Inhibidores de ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp1) y usos de los mismos

Country Status (12)

Country Link
US (1) US20250101019A1 (https=)
EP (1) EP4469456A4 (https=)
JP (1) JP2025502943A (https=)
KR (1) KR20240142481A (https=)
CN (1) CN118871439A (https=)
AR (1) AR128383A1 (https=)
AU (1) AU2023213905A1 (https=)
CA (1) CA3247162A1 (https=)
IL (1) IL313821A (https=)
MX (1) MX2024009216A (https=)
TW (1) TW202340190A (https=)
WO (1) WO2023143520A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024074128A1 (en) * 2022-10-08 2024-04-11 Insilico Medicine Ip Limited Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp1) inhibitors and uses thereof
CN121793967A (zh) * 2023-07-06 2026-04-03 英矽智能科技知识产权有限公司 外切核苷酸焦磷酸酶/磷酸二酯酶1 (enpp1)抑制剂组合及其用途
CN121969621A (zh) * 2023-08-02 2026-05-01 英矽智能科技知识产权有限公司 外核苷酸焦磷酸酶-磷酸二酯酶1 (enpp1)抑制剂的结晶形式及其用途
WO2025026377A1 (en) * 2023-08-02 2025-02-06 Insilico Medicine Ip Limited Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp1) inhibitors and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT98674B (pt) * 1990-08-15 1999-01-29 British Bio Technology Processo para a preparacao de compostos que sao antagonistas do factor de activacao de plaquetas por exemplo derivados de imidazole e de seus intermedriarios
GB9200209D0 (en) * 1992-01-07 1992-02-26 British Bio Technology Compounds
US6489338B2 (en) * 2000-06-13 2002-12-03 Bristol-Myers Squibb Company Imidazopyridine and imidazopyrimidine antiviral agents
KR101142363B1 (ko) * 2005-06-27 2012-05-21 주식회사유한양행 피롤로피리딘 유도체를 포함하는 항암제 조성물
PE20081354A1 (es) * 2006-11-30 2008-11-14 Genentech Inc Compuestos de azaindolilo como inhibidores de mek
WO2015038417A1 (en) * 2013-09-10 2015-03-19 Asana Biosciences, Llc Compounds for regulating fak and/or src pathways
WO2019023635A1 (en) * 2017-07-27 2019-01-31 Stingray Therapeutics, Inc. SUBSTITUTED 3 H-IMIDAZO (4,5-C) PYRIDINE AND 1H-PYRROLO (2,3-C) PYRIDINE SERIES OF A NOVEL ECTONUCLEOTIDE PYROPHOSPHATASE / PHOSPHODIESTERASE-1 (ENPP1) AND STIMULATOR FOR A GENE MODULATOR INTERFERON (STING) AS IMMUNOTHERAPEUTIC AGENTS AGAINST CANCER
CN111732584B (zh) * 2019-03-25 2024-02-27 复旦大学 二芳基取代稠杂环类化合物及其制备方法和在制药中的用途
ES2960987T3 (es) * 2019-04-12 2024-03-07 Riboscience Llc Derivados de heteroarilo bicíclicos como inhibidores de la ectonucleótido pirofosfatasa fosfodiesterasa 1
KR20220068243A (ko) * 2019-09-23 2022-05-25 난징 젱시앙 파마슈티칼스 컴퍼니 리미티드 포스포디에스테라제 억제제 및 용도
MX2023008761A (es) * 2021-01-29 2023-08-22 Txinno Bioscience Inc Derivado de benzotriazol novedoso que posee actividad inhibitoria contra la ectonucleotido pirofosfatasa - fosfodiesterasa y uso del mismo.

Also Published As

Publication number Publication date
IL313821A (en) 2024-08-01
JP2025502943A (ja) 2025-01-30
AU2023213905A1 (en) 2024-07-11
WO2023143520A1 (en) 2023-08-03
US20250101019A1 (en) 2025-03-27
CN118871439A (zh) 2024-10-29
EP4469456A1 (en) 2024-12-04
TW202340190A (zh) 2023-10-16
KR20240142481A (ko) 2024-09-30
EP4469456A4 (en) 2025-12-31
CA3247162A1 (en) 2023-08-03
MX2024009216A (es) 2024-08-06

Similar Documents

Publication Publication Date Title
AR128383A1 (es) Inhibidores de ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp1) y usos de los mismos
AR128668A1 (es) INHIBIDORES DE DIACILGLICEROL CINASA (DGK) a Y USOS DE LOS MISMOS
AR128669A1 (es) INHIBIDORES DE DIACILGLICEROL CINASA (DGK) a Y USOS DE LOS MISMOS
AR127500A1 (es) Inhibidores de la proteína que contiene el dominio de prolil hidroxilasa (phd) y usos de los mismos
AR124483A2 (es) Compuestos heterocíclicos útiles como inhibidores de pdk1
AR111407A1 (es) Compuestos inhibidores de ask1 y usos de los mismos
AR092536A1 (es) Inhibidores de la tirosina-quinasa de bruton
AR117264A1 (es) Esteroides neuroactivos y métodos para su uso
AR068109A1 (es) Derivados tetraciclicos de indol y una composicion farmaceutica
AR085958A1 (es) 8-etil-6-(aril)pirido[2,3-d]pirimidin-7(8h)-onas para el tratamiento de trastornos del cns y cancer
AR064428A1 (es) Derivados indolicos con anillo unido en las posiciones 4,5 y sus metodos de uso. composiciones farmaceuticas
AR094816A2 (es) Compuestos antivirales
AR096979A1 (es) Derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
AR110298A1 (es) Compuestos de heterociclo tetracíclicos útiles como inhibidores de la integrasa del vih
AR108710A1 (es) Compuestos modulares de fxr (nr1h4)
AR095464A1 (es) Compuestos de heteroarilo y usos de los mismos
AR068106A1 (es) Derivados de indol 2-carboxi sustituidos y una composicion farmaceutica
AR099177A1 (es) Determinadas (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1
AR078609A1 (es) 8-etil-6-(aril)pirido[2,3-d]pirimidin-7(8h)-onas, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de trastornos del sistema nervioso central,tales como depresion y canceres de ovario y renales, entre otros.
AR099914A1 (es) Derivados de indol y de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
AR119305A1 (es) Composiciones y métodos para el tratamiento de los trastornos del snc
AR116695A1 (es) Los neuroesteroides y sus métodos de uso
AR121715A1 (es) Pirrolopirimidinaminas como inhibidores del sistema del complemento
AR088246A1 (es) Derivados de etinilo
AR116905A1 (es) Derivados de ácido pirrolidino-2-carboxílico para tratar el dolor y afecciones relacionadas con el dolor